How big is Agios Pharmaceuticals, Inc.?

As of Jun 18, Agios Pharmaceuticals, Inc. has a market capitalization of $2.56 billion, with net sales of $37.04 million and a net profit of $665.98 million over the latest four quarters.

Market Cap: As of Jun 18, Agios Pharmaceuticals, Inc. has a market capitalization of 2,557.19 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Agios Pharmaceuticals, Inc. reported net sales of 37.04 million and a net profit of 665.98 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,540.96 million and total assets of 1,663.20 million.

What does Agios Pharmaceuticals, Inc. do?

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare genetic metabolic disorders. As of March 2025, it reported net sales of $9 million and a net loss of $89 million, with a market cap of $2.56 billion.

Overview:<BR>Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare genetic metabolic disorders within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 9 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -89 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 2,557.19 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 4.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.60 <BR>Return on Equity: 45.41% <BR>Price to Book: 1.74<BR><BR>Contact Details:<BR>Address: 88 Sidney St, CAMBRIDGE MA: 02139-4137 <BR>Tel: ['1 617 6498600', '1 617 844-6630'] <BR>Fax: 1 302 6555049 <BR>Website: http://www.agios.com/

Who are in the management team of Agios Pharmaceuticals, Inc.?

As of March 2022, the management team of Agios Pharmaceuticals, Inc. includes Dr. David Schenkein (Executive Chairman), Dr. Jacqualyn Fouse (CEO), Dr. David Scadden, and independent directors Paul Clancy, Ian Clark, Kaye Foster, and Maykin Ho. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of Agios Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. David Schenkein, who serves as the Executive Chairman of the Board.<BR>- Dr. Jacqualyn Fouse, who is the Chief Executive Officer and a Director.<BR>- Dr. David Scadden, who is a Director.<BR>- Mr. Paul Clancy, who is an Independent Director.<BR>- Mr. Ian Clark, who is also an Independent Director.<BR>- Ms. Kaye Foster, who serves as an Independent Director.<BR>- Dr. Maykin Ho, who is another Independent Director.<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Should I buy, sell or hold Agios Pharmaceuticals, Inc.?

Is Agios Pharmaceuticals, Inc. technically bullish or bearish?

As of October 3, 2025, Agios Pharmaceuticals shows a bullish technical trend with strong momentum indicators, outperforming the S&P 500 in the short term, though it has underperformed over the long term.

As of 3 October 2025, the technical trend for Agios Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, and the monthly RSI is also bullish, indicating strong momentum. Bollinger Bands are bullish on both weekly and monthly time frames, further supporting the bullish stance. Daily moving averages are bullish as well. However, the KST shows a mildly bearish signal on both weekly and monthly time frames, and Dow Theory indicates a mildly bullish trend on a monthly basis. <BR><BR>In terms of performance, Agios has outperformed the S&P 500 over the past week and month, with returns of 4.13% and 13.55% respectively, compared to 1.09% and 4.15% for the index. However, over the longer term, the stock has underperformed the S&P 500 on a 1-year, 3-year, 5-year, and 10-year basis. Overall, the current technical stance is bullish, with strong indicators supporting this view.

Is Agios Pharmaceuticals, Inc. overvalued or undervalued?

As of October 17, 2025, Agios Pharmaceuticals, Inc. is considered attractive due to its undervalued status, reflected in a low P/E ratio of 4, a PEG ratio of 0.01, and strong year-to-date returns of 28.82%, outperforming the S&P 500.

As of 17 October 2025, the valuation grade for Agios Pharmaceuticals, Inc. has changed from very attractive to attractive, indicating a shift in market perception. The company appears to be undervalued, with a P/E ratio of 4, a PEG ratio of 0.01, and an EV to EBITDA ratio of -3.81, which suggests that the stock may be trading at a significant discount relative to its earnings potential. <BR><BR>In comparison to its peers, Agios has a lower P/E ratio than PTC Therapeutics, Inc. at 5.85 and Crinetics Pharmaceuticals, Inc. at -8.95, indicating that it is relatively cheaper in terms of earnings. The company's return performance shows a 1-week return of 4.24% compared to the S&P 500's 1.70%, and a year-to-date return of 28.82% against the S&P 500's 13.30%, which reinforces the notion that the stock may be undervalued.